Phillip Md Et Al Frost Buys 47,537 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

Posted by Michael Baxter on Jan 29th, 2025

OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) CEO Phillip Md Et Al Frost bought 47,537 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were bought at an average price of $1.47 per share, with a total value of $69,879.39. Following the completion of the transaction, the chief executive officer now owns 213,234,014 shares in the company, valued at approximately $313,454,000.58. This trade represents a 0.02 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.47 per share, with a total value of $220,500.00.
On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, for a total transaction of $740,000.00.
On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, with a total value of $198,750.00.
On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.56 per share, for a total transaction of $780,000.00.
On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were purchased at an average price of $1.53 per share, with a total value of $304,580.16.
On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.59 per share, for a total transaction of $159,000.00.
On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was acquired at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Up 2.0 %

Shares of OPKO Health stock traded up $0.03 on Tuesday, hitting $1.50. The stock had a trading volume of 2,064,740 shares, compared to its average volume of 2,534,497. The stock has a 50 day moving average of $1.53 and a 200 day moving average of $1.52. The firm has a market capitalization of $1.02 billion, a P/E ratio of -7.89 and a beta of 1.63. OPKO Health, Inc. has a twelve month low of $0.86 and a twelve month high of $1.76. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $173.60 million during the quarter, compared to the consensus estimate of $181.32 million. During the same quarter last year, the firm earned ($0.11) earnings per share. Sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently made changes to their positions in the stock. FMR LLC raised its stake in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Private Advisor Group LLC grew its holdings in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 25,000 shares during the period. Orion Portfolio Solutions LLC bought a new position in shares of OPKO Health in the 3rd quarter worth about $45,000. Algert Global LLC acquired a new position in shares of OPKO Health in the 2nd quarter valued at about $44,000. Finally, World Investment Advisors LLC bought a new stake in shares of OPKO Health during the 3rd quarter valued at about $61,000. Institutional investors own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OPK. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th.

Get Our Latest Report on OPK

About OPKO Health

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.